Should I Buy EW? EW 2026 Analysis

Should You Buy Edwards Lifesciences Corp (EW) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

78.710

1 Day change

0.78%

52 Week Range

87.890

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price momentum is still bearish and options positioning is defensively skewed into earnings.
Best read today is “wait/hold” rather than chase: EW is sitting on/near key support (79–81 zone) but MACD is still accelerating lower, so downside follow-through is plausible before a durable bounce.
Wall Street setup is constructive (multiple recent upgrades/target raises), but the near-term tape and options market are signaling caution.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: Bearish in the near term — MACD histogram is negative (-0.317) and expanding lower, consistent with an active downswing.
RSI: RSI(6) at 27.48 indicates oversold conditions (bounce risk), but oversold alone is not a reversal signal while MACD is still worsening.
Moving averages: Converging MAs suggest consolidation risk, but currently not a confirmed uptrend.
Key levels: Price ~79.77 is below S1 (80.553) and near S2 (79.091). A clean hold above ~79.1 could spark a technical bounce; a break below increases risk of another leg down. Pivot resistance sits much higher at ~82.92 (a key reclaim level).

Options Data

Bearish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Sentiment/Positioning: Put-heavy (OI PCR 2.03; Volume PCR 4.98) = defensive/bearish near-term positioning.
Activity: Options volume is extremely elevated (today vs 30D avg ~293.6%), suggesting an event-driven market (earnings/FDA catalysts).
Volatility: 30D IV ~42.94 vs historical vol ~18.22; IV percentile ~89.64 = options are pricing a large move.
Interpretation: Despite a news-noted bullish risk-reversal (call buying funded by put selling), today’s aggregate put skew and very high IV argue the market is still demanding protection into the catalyst window.

Technical Summary

Sell

Buy

Positive Catalysts

- Event-driven upside potential: News highlights institutional bullish positioning via risk reversal (buying $92.50 calls / selling $82.50 puts).
- Pipeline/regulatory catalyst: Anticipated FDA approval for a new device (per news summary).
- Growth pocket: Transcatheter Mitral & Tricuspid Therapies unit cited as +57% YoY (per news summary).
- Capital return support: $500M share repurchase program (per news summary).
- Upcoming catalyst: Q4 earnings on 2026-02-10 after hours (potential re-rating if guide/beat).

Neutral/Negative Catalysts

- Near-term technical pressure: Down day (-2.86%) with bearish MACD expansion suggests sellers still in control.
- Options market caution: Very high IV and heavy put skew implies traders are braced for downside or hedging aggressively into earnings.
- Pattern-based short-term drift: Similar-pattern model implies ~-3.19% over the next week (near-term headwind).
- Earnings proximity: With earnings days away, price may remain pinned/volatile and vulnerable to disappointment (market is pricing a big move).

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $1.553B, up +14.67% YoY (solid top-line growth).
Profitability: Net income $291.1M, down -90.52% YoY; EPS $0.50, down -90.25% YoY (major compression vs prior year).
Margins: Gross margin 77.77%, down -3.50% YoY (mild deterioration).
Takeaway: Strong revenue growth, but the sharp earnings decline is a near-term fundamental overhang unless investors view it as non-recurring or already understood.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings/targets have turned more bullish from mid-Dec through Jan with multiple upgrades and target raises.
Notable actions: TD Cowen upgraded to Buy (PT $97); JPMorgan upgraded to Overweight (PT $100); Goldman raised PT to $108 (Buy); Stifel raised PT to $110 (Buy); Piper raised PT to $98 (Overweight); Barclays raised PT to $103 (Overweight); Citi raised PT to $101 (Buy).
Wall Street pros view: Renewed growth cycle narrative (TAVR expansion, durability data, Evoque momentum) and pipeline-driven catalysts.
Wall Street cons view: Some neutrals remain (e.g., Baird/Canaccord holds) and macro/policy risk is cited for the broader MedTech group; near-term earnings/guide execution is the key proof point.

24 Analyst Rating

Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 96.52 USD with a low forecast of 84 USD and a high forecast of 105 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

8 Hold

0 Sell

Moderate Buy

Current: 78.100

Low

Averages

96.52

High

105

Current: 78.100

Low

Averages

96.52

High

105

UBS

Danielle Antalffy

Neutral

downgrade

$95 -> $94

AI Analysis

2026-02-04

New

Reason

UBS

Danielle Antalffy

Price Target

$95 -> $94

AI Analysis

2026-02-04

New

downgrade

Neutral

Reason

UBS analyst Danielle Antalffy lowered the firm's price target on Edwards Lifesciences to $94 from $95 and keeps a Neutral rating on the shares.

Stifel

Buy

maintain

$105 -> $110

2026-01-20

Reason

Stifel

Price Target

$105 -> $110

2026-01-20

maintain

Buy

Reason

Stifel raised the firm's price target on Edwards Lifesciences to $110 from $105 and keeps a Buy rating on the shares, reporting that the firm's fifty physician TAVR survey results were "highly encouraging for TAVR growth as a whole and Edwards specifically."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EW

Unlock Now

EW Should I Buy

EW Should I Buy

Should You Buy Edwards Lifesciences Corp (EW) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch